Hypoglycemia - Pipeline Review, H2 2015
Summary
Global Markets Direct’s, ‘Hypoglycemia - Pipeline Review, H2 2015’, provides an overview of the Hypoglycemia’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Hypoglycemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypoglycemia and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hypoglycemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hypoglycemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hypoglycemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hypoglycemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hypoglycemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hypoglycemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hypoglycemia Overview 7
Therapeutics Development 8
Pipeline Products for Hypoglycemia - Overview 8
Pipeline Products for Hypoglycemia - Comparative Analysis 9
Hypoglycemia - Therapeutics under Development by Companies 10
Hypoglycemia - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Hypoglycemia - Products under Development by Companies 14
Hypoglycemia - Companies Involved in Therapeutics Development 15
Biodel Inc. 15
Eli Lilly and Company 16
Heptares Therapeutics Limited 17
Novartis AG 18
SkyePharma Plc 19
USV Limited 20
XERIS Pharmaceuticals, Inc. 21
XOMA Corporation 22
Zealand Pharma A/S 23
Hypoglycemia - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
Biologic for Hypoglycemia - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
glucagon - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
glucagon - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
glucagon - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
glucagon - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
glucagon - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
pasireotide - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecule to Antagonize GLP-1 Receptor Hypoglycemia - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
terbutaline sulphate - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
XOMA-358 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ZP-4207 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Hypoglycemia - Recent Pipeline Updates 47
Hypoglycemia - Dormant Projects 53
Hypoglycemia - Discontinued Products 54
Hypoglycemia - Product Development Milestones 55
Featured News & Press Releases 55
Jun 26, 2015: Phase I trial results for Zealand’s glucagon analogue, ZP4207 support its further development as a ready-to-use rescue treatment for severe hypoglycemia in diabetes patients on insulin therapy 55
Jun 23, 2015: Zosano Pharma Completes Enrollment in Phase 2 Trial for ZP-Glucagon, Its Microneedle Patch for Treatment of Severe Hypoglycemia 56
May 20, 2015: Zealand starts clinical development of a multiple-dose version of its stable glucagon analogue, ZP4207 56
Mar 16, 2015: Biodel's Glucagon Formulation for Use in a Proprietary Auto-Reconstitution Device for the Treatment of Severe Hypoglycemia Meets Primary Efficacy Endpoint in Phase 1 Clinical Trial 57
Mar 07, 2015: XOMA Presents Positive Phase 1 XOMA 358 Data at the ENDO Meeting 59
Mar 05, 2015: XOMA Will Present XOMA 358 Phase 1 Data at ENDO 2015 59
Dec 04, 2014: Biodel Initiates Clinical Proof of Concept Study in Glucagon Emergency Management Program 60
Nov 17, 2014: Zealand advances its proprietary stable glucagon analogue for severe hypoglycemia in diabetes into clinical development 60
Jun 17, 2014: Zealand presented new data on ZP-GA-1 novel peptide therapeutics from its preclinical diabetes pipeline at the American Diabetes Association’s (ADA) 74th Scientific Sessions 61
Jul 03, 2013: Biodel to Present New Preclinical Glucagon Data During Corporate Overview at JMP Securities Healthcare Conference 62
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 63
Disclaimer 6
List Of Tables
Number of Products under Development for Hypoglycemia, H2 2015 8
Number of Products under Development for Hypoglycemia - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Comparative Analysis by Late Stage Development, H2 2015 11
Comparative Analysis by Clinical Stage Development, H2 2015 12
Comparative Analysis by Early Stage Development, H2 2015 13
Products under Development by Companies, H2 2015 14
Hypoglycemia - Pipeline by Biodel Inc., H2 2015 15
Hypoglycemia - Pipeline by Eli Lilly and Company, H2 2015 16
Hypoglycemia - Pipeline by Heptares Therapeutics Limited, H2 2015 17
Hypoglycemia - Pipeline by Novartis AG, H2 2015 18
Hypoglycemia - Pipeline by SkyePharma Plc, H2 2015 19
Hypoglycemia - Pipeline by USV Limited, H2 2015 20
Hypoglycemia - Pipeline by XERIS Pharmaceuticals, Inc., H2 2015 21
Hypoglycemia - Pipeline by XOMA Corporation, H2 2015 22
Hypoglycemia - Pipeline by Zealand Pharma A/S, H2 2015 23
Assessment by Monotherapy Products, H2 2015 24
Number of Products by Stage and Target, H2 2015 26
Number of Products by Stage and Mechanism of Action, H2 2015 28
Number of Products by Stage and Route of Administration, H2 2015 30
Number of Products by Stage and Molecule Type, H2 2015 32
Hypoglycemia Therapeutics - Recent Pipeline Updates, H2 2015 47
Hypoglycemia - Dormant Projects, H2 2015 53
Hypoglycemia - Discontinued Products, H2 2015 54
List Of Figures
Number of Products under Development for Hypoglycemia, H2 2015 8
Number of Products under Development for Hypoglycemia - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 12
Comparative Analysis by Early Stage Products, H2 2015 13
Assessment by Monotherapy Products, H2 2015 24
Number of Products by Top 10 Targets, H2 2015 25
Number of Products by Stage and Top 10 Targets, H2 2015 25
Number of Products by Top 10 Mechanism of Actions, H2 2015 27
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 27
Number of Products by Top 10 Routes of Administration, H2 2015 29
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 29
Number of Products by Top 10 Molecule Types, H2 2015 31
Number of Products by Stage and Top 10 Molecule Types, H2 2015 31
